Clinical Trials Browser

Phase 2/3 × Active not recruiting × OTHER × Clear all

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT02491632 2026-03-18

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

Phase 2/3 Active not recruiting

90 enrolled 13 charts

Fatigue, Neoplasm Metastasis, Neoplasms, Recurrence

NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

Phase 2/3 Active not recruiting

70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT07434206 2026-02-25

Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors

Phase 2/3 Active not recruiting

Thyroid Neoplasms

NCT03927885 2026-02-19

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Phase 2/3 Active not recruiting

Neoplasm Metastasis

NCT03686202 2026-02-09

MET4-IO

Phase 2/3 Active not recruiting

Other solid neoplasm

All Solid Tumors

NCT04137107 2026-01-26

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colonic Neoplasms

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Phase 2/3 Active not recruiting

Delirium, Neoplasm Metastasis, Recurrence

NCT05902533 2025-12-18

REDEL

Phase 2/3 Active not recruiting

Gastrointestinal

Anus Neoplasms

NCT01046825 2025-12-10

Mature B-Cell Lymphoma And Leukemia Study III

Phase 2/3 Active not recruiting

128 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Phase 2/3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02066220 2025-12-04

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Phase 2/3 Active not recruiting

Brain Neoplasms, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT06100367 2025-12-02

11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours

Phase 2/3 Active not recruiting

Adrenal Gland Neoplasms, Hyperaldosteronism, Neoplasm Metastasis

NCT03637816 2025-11-03

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

Anorexia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03772834 2025-10-10

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT04669496 2025-09-04

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT03326791 2025-07-31

ASAC

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05356169 2025-05-30

Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Phase 2/3 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Phase 2/3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04068103 2025-05-07

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Phase 2/3 Active not recruiting

635 enrolled 9 charts

Gastrointestinal

Colonic Neoplasms

NCT02945566 2025-03-27

STAR-TREC

Phase 2/3 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT03525288 2025-03-13

PSMA-PETgRT

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT02600208 2025-02-19

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

Phase 2/3 Active not recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT02984124 2025-02-18

CHART

Phase 2/3 Active not recruiting

Kidney Failure, Chronic

NCT03081143 2024-12-12

RAMIRIS

Phase 2/3 Active not recruiting

Gastrointestinal

Advanced Gastric or EGJ Cancer

NCT02685397 2024-12-04

PCS IX

Phase 2/3 Active not recruiting

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT05889390 2024-12-03

NeoHTerMa

Phase 2/3 Active not recruiting

Hyperthermia, Breast Neoplasms

NCT02758951 2024-11-25

CAIRO6

Phase 2/3 Active not recruiting

GastrointestinalGynecologic

Hyperthermia, Colonic Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT02919787 2024-11-20

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Phase 2/3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2/3 Active not recruiting

HER2-positive Breast Cancer

NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Phase 2/3 Active not recruiting

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01398085 2024-05-08

IoN

Phase 2/3 Active not recruiting

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

Phase 2/3 Active not recruiting

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01057069 2022-10-12

neo-TN

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02568839 2020-08-13

PREDIX HER2

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02482454 2017-08-01

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma